Cognitive Behavioral Therapy Plus Drug Treatment for Obsessive Compulsive Disorder

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

136 participants

Study Classification

INTERVENTIONAL

Study Start Date

2000-08-31

Study Completion Date

2007-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will evaluate the effectiveness of two cognitive behavioral therapies (CBTs) in treating obsessive compulsive disorder (OCD) in patients who are taking medication but still have residual symptoms.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Mindfulness-Based Cognitive Therapy in a Clinical Sample of OCD Patients

NCT02217995

Obsessive-Compulsive Disorder

COMPLETED NA

Family Based Treatment of Early Childhood Obsessive Compulsive Disorder

NCT00055068

Obsessive-Compulsive Disorder

COMPLETED PHASE3

Behavior Therapy for Children and Adolescents With Obsessive-Compulsive Disorder (OCD)

NCT00000386

Obsessive-Compulsive Disorder

COMPLETED PHASE3

Personalized Computerized Inhibitory Control Training for OCD

NCT02378896

Obsessive-Compulsive Disorder

COMPLETED NA

Stepped Care for Treating Obsessive-Compulsive Disorder

NCT00316355

Obsessive-compulsive Disorder

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Participants remain on their current OCD medication and are randomly assigned to receive one of two CBTs: exposure and ritual prevention or stress management therapy. Exposure and ritual prevention involves imaginal and in-vivo exposure and requires that participants refrain from ritualizing. Stress management involves relaxation, assertiveness training, and structured problem-solving. Therapy occurs twice per week for 2 months. Participants are assessed verbally by an independent evaluator and are asked to complete self-rating forms. Patients who respond are followed for up to 1 additional year. Participants continue to take the same medication and the same monthly therapy for the first 6 months of follow-up. During the second 6 months of follow-up, participants discontinue therapy but continue taking the same medication.

For information on a related study, please follow this link:

http://clinicaltrials.gov/show/NCT00389493

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obsessive-Compulsive Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Exposure and Ritual Prevention

Exposure and Ritual Prevention Therapy

Group Type EXPERIMENTAL

Exposure and Ritual Prevention (Cognitive Behavioral Therapy)

Intervention Type BEHAVIORAL

Stress Management

Stress Management Therapy

Group Type ACTIVE_COMPARATOR

Stress Management Therapy (Cognitive Behavior Therapy)

Intervention Type BEHAVIORAL

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Exposure and Ritual Prevention (Cognitive Behavioral Therapy)

Intervention Type BEHAVIORAL

Stress Management Therapy (Cognitive Behavior Therapy)

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Obsessive-Compulsive Disorder (OCD) diagnosis
* Currently taking a serotonin reuptake inhibitor (SRI, i.e. clomipramine, fluoxetine, fluvoxamine, paroxetine, sertraline, or citalopram) for OCD

Exclusion Criteria

* Medical or psychiatric conditions that would make participation in the study hazardous
* Intensive cognitive-behavioral therapy while on an adequate dose and duration of an SRI for OCD

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No